Vivoryon Therapeutics N.V.
Healthcare · EUR · AMS
Price
€1.24
Cap
€16.59M
Earnings
—
30d Trend
-6.8%
31% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 34×Macro 0.99 (−1%)=34
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
19-day catalyst play — earnings window
BRAIN47'S ASSESSMENT
I rate Vivoryon Therapeutics N.V. at 34/100 — a WEAK reading on the Brain47 Signal. The strongest factor is risk management at 50/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.
PAST PERFORMANCE
1 MONTH
-3.1%
3 MONTHS
-12.0%
12 MONTHS
-27.1%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
19-day catalyst play — earnings window. low-risk profile and Technical (41) are the primary strengths. I note that quality is the weakest area at 15/100 — this warrants monitoring. Historical volatility is moderate at 31%. I classify this as a speculative position — risk characteristics and smaller market cap define the opportunity.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.